Literature DB >> 11125899

CCR5 delta32 deletion and response to highly active antiretroviral therapy in HIV-1-infected patients.

S Guérin1, L Meyer, I Theodorou, F Boufassa, M Magierowska, C Goujard, C Rouzioux, P Debré, J F Delfraissy.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 11125899     DOI： 10.1097/00002030-200012010-00020

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


× No keyword cloud information.
  12 in total

1.  Virologic and Immunologic Response to Highly Active Antiretroviral Therapy.

Authors:  Lisa P. Jacobson; John P. Phair; Traci E. Yamashita
Journal:  Curr Infect Dis Rep       Date:  2002-02       Impact factor: 3.725

2.  Update on the Virologic and Immunologic Response to Highly Active Antiretroviral Therapy.

Authors:  Lisa P. Jacobson; John P. Phair; Traci E. Yamashita
Journal:  Curr Infect Dis Rep       Date:  2004-08       Impact factor: 3.725

Review 3.  Virologic and immunologic response to highly active antiretroviral therapy.

Authors:  Lisa P Jacobson; John P Phair; Traci E Yamashita
Journal:  Curr HIV/AIDS Rep       Date:  2004-06       Impact factor: 5.071

4.  Distribution of chemokine receptor CCR2 and CCR5 genotypes and their relative contribution to human immunodeficiency virus type 1 (HIV-1) seroconversion, early HIV-1 RNA concentration in plasma, and later disease progression.

Authors:  Jianming Tang; Brent Shelton; Nina J Makhatadze; Yuting Zhang; Margaret Schaen; Leslie G Louie; James J Goedert; Eric C Seaberg; Joseph B Margolick; John Mellors; Richard A Kaslow
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

5.  Reply to: "Experimental aspects of copy number variant assays at CCL3L1".

Authors:  Weijing He; Hemant Kulkarni; John Castiblanco; Chisato Shimizu; Una Aluyen; Robert Maldonado; Andrew Carrillo; Madeline Griffin; Amanda Lipsitt; Lisa Beachy; Ludmila Shostakovich-Koretskaya; Andrea Mangano; Luisa Sen; Robert J B Nibbs; Caroline T Tiemessen; Hector Bolivar; Michael J Bamshad; Robert A Clark; Jane C Burns; Matthew J Dolan; Sunil K Ahuja
Journal:  Nat Med       Date:  2009-10       Impact factor: 53.440

6.  Chemokine (C-C motif) receptor 5 -2459 genotype in patients receiving highly active antiretroviral therapy: race-specific influence on virologic success.

Authors:  Rajeev K Mehlotra; Vinay K Cheruvu; Melinda J Blood Zikursh; Rebekah L Benish; Michael M Lederman; Robert A Salata; Barbara Gripshover; Grace A McComsey; Michelle V Lisgaris; Scott Fulton; Carlos S Subauste; Richard J Jurevic; Chantal Guillemette; Peter A Zimmerman; Benigno Rodriguez
Journal:  J Infect Dis       Date:  2011-07-15       Impact factor: 5.226

7.  Is long-term virological response related to CCR5 Delta32 deletion in HIV-1-infected patients started on highly active antiretroviral therapy?

Authors:  J-J Laurichesse; A Taieb; C Capoulade-Metay; C Katlama; V Villes; M-C Drobacheff-Thiebaud; F Raffi; G Chêne; I Theodorou; C Leport
Journal:  HIV Med       Date:  2009-12-28       Impact factor: 3.180

8.  PSC-RANTES blocks R5 human immunodeficiency virus infection of Langerhans cells isolated from individuals with a variety of CCR5 diplotypes.

Authors:  Tatsuyoshi Kawamura; Shannon E Bruse; Awet Abraha; Makoto Sugaya; Oliver Hartley; Robin E Offord; Eric J Arts; Peter A Zimmerman; Andrew Blauvelt; Shannon E Bruce
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

9.  Host genetic influences on highly active antiretroviral therapy efficacy and AIDS-free survival.

Authors:  Sher L Hendrickson; Lisa P Jacobson; George W Nelson; John P Phair; James Lautenberger; Randall C Johnson; Lawrence Kingsley; Joseph B Margolick; Roger Detels; James J Goedert; Stephen J O'Brien
Journal:  J Acquir Immune Defic Syndr       Date:  2008-07-01       Impact factor: 3.731

10.  Analysis of the CCR5 gene coding region diversity in five South American populations reveals two new non-synonymous alleles in Amerindians and high CCR5*D32 frequency in Euro-Brazilians.

Authors:  Angelica B W Boldt; Lodércio Culpi; Luiza T Tsuneto; Ilíada R Souza; Jürgen F J Kun; Maria Luiza Petzl-Erler
Journal:  Genet Mol Biol       Date:  2009-01-16       Impact factor: 1.771
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.